These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
893 related articles for article (PubMed ID: 26083531)
21. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913 [TBL] [Abstract][Full Text] [Related]
22. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption. Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279 [TBL] [Abstract][Full Text] [Related]
23. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways. Nie S; Xu J; Zhang C; Xu C; Liu M; Yu D Biochem Biophys Res Commun; 2016 Jan; 470(1):61-67. PubMed ID: 26740180 [TBL] [Abstract][Full Text] [Related]
24. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression. Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100 [TBL] [Abstract][Full Text] [Related]
25. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities. Jiang C; Shang J; Li Z; Qin A; Ouyang Z; Qu X; Li H; Tian B; Wang W; Wu C; Wang J; Dai M J Cell Physiol; 2016 Jan; 231(1):142-51. PubMed ID: 26060084 [TBL] [Abstract][Full Text] [Related]
26. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages. Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094 [TBL] [Abstract][Full Text] [Related]
27. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ). Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059 [TBL] [Abstract][Full Text] [Related]
29. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos. Ha J; Choi HS; Lee Y; Lee ZH; Kim HH Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574 [TBL] [Abstract][Full Text] [Related]
30. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells. Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020 [TBL] [Abstract][Full Text] [Related]
31. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation. Chiou WF; Huang YL; Liu YW PLoS One; 2014; 9(2):e89159. PubMed ID: 24558484 [TBL] [Abstract][Full Text] [Related]
32. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045 [TBL] [Abstract][Full Text] [Related]
33. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages. Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286 [TBL] [Abstract][Full Text] [Related]
34. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722 [TBL] [Abstract][Full Text] [Related]
35. Decursin from Angelica gigas suppresses RANKL-induced osteoclast formation and bone loss. Wang X; Zheng T; Kang JH; Li H; Cho H; Jeon R; Ryu JH; Yim M Eur J Pharmacol; 2016 Mar; 774():34-42. PubMed ID: 26825541 [TBL] [Abstract][Full Text] [Related]
36. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways. He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381 [TBL] [Abstract][Full Text] [Related]
37. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages. Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379 [TBL] [Abstract][Full Text] [Related]
38. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
39. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts. Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739 [TBL] [Abstract][Full Text] [Related]
40. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression. Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]